{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:25:25Z","timestamp":1787019925659,"version":"build-2736575974"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), a major international public health concern. Because of very similar amino acid sequences of the seven domain names, SARS-CoV-2 belongs to the Coronavirinae subfamily of the family Coronaviridae, order Nidovirales, and realm Riboviria, placed in exceptional clusters, but categorized as a SARS-like species. As the RNA virus family with the longest genome, the Coronaviridae genome consists of a single strand of positive RNA (25\u201332\u00a0kb in length). Four major structural proteins of this genome include the spike (S), membrane (M), envelope (E), and the nucleocapsid (N) protein, all of which are encoded within the 3\u2032 end of the genome. By engaging with its receptor, angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 infects host cells. According to the most recent epidemiological data, as the illness spread globally, several genetic variations of SARS-CoV-2 appeared quickly, with the World Health Organization (WHO) naming 11 of them. Among these, seven SARS-CoV-2 subtypes have received the most attention. Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.617.2) are now designated as variations of concern (VOC) (B.1.1.529). Lambda (C.37) and Mu are variations of interest (VOI) (B.1.621). The remaining six are either being monitored or are no longer considered a threat. On the basis of studies done so far, antiviral drugs, antibiotics, glucocorticoids, recombinant intravenous immunoglobulin, plasma therapy, and IFN-\u03b12b have been used to treat patients. Moreover, full vaccination is associated with lower infection and helps prevent transmission, but the risk of infection cannot be eliminated completely in vaccinated people.<\/jats:p>","DOI":"10.1186\/s11658-022-00352-6","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:26:36Z","timestamp":1655450796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["SARS-CoV-2: phenotype, genotype, and characterization of different variants"],"prefix":"10.1186","volume":"27","author":[{"given":"Mohammadreza","family":"Saberiyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvaneh","family":"Movahhed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Mehri-Ghahfarrokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"8","key":"352_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et\u00a0al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"key":"352_CR2","unstructured":"Rajnik M, Cascella M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Uniformed Services University Of The Health Sciences; 2021."},{"issue":"4","key":"352_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418\u201323.","journal-title":"J Med Virol"},{"issue":"3","key":"352_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181\u201392.","journal-title":"Nat Rev Microbiol"},{"issue":"9393","key":"352_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","volume":"362","author":"N Zhong","year":"2003","unstructured":"Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et\u00a0al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353\u20138.","journal-title":"Lancet"},{"issue":"20","key":"352_CR6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa030781","volume":"348","author":"TG Ksiazek","year":"2003","unstructured":"Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et\u00a0al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953\u201366.","journal-title":"N Engl J Med"},{"issue":"20","key":"352_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten C, G\u00fcnther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et\u00a0al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967\u201376.","journal-title":"N Engl J Med"},{"issue":"1","key":"352_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/v11010059","volume":"11","author":"Z Song","year":"2019","unstructured":"Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et\u00a0al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59.","journal-title":"Viruses"},{"issue":"3","key":"352_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/09273948.2020.1738501","volume":"28","author":"I Seah","year":"2020","unstructured":"Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;28(3):391\u20135.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"352_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2020.100618","volume":"45","author":"S Zaim","year":"2020","unstructured":"Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8): 100618.","journal-title":"Curr Probl Cardiol"},{"key":"352_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102463","volume":"112","author":"G Li","year":"2020","unstructured":"Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et\u00a0al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020;112: 102463.","journal-title":"J Autoimmun"},{"key":"352_CR12","unstructured":"World Health Organization. 2022. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants."},{"key":"352_CR13","unstructured":"International Committee on Taxonomy of Viruses (ICTV). 2022. https:\/\/talk.ictvonline.org\/taxonomy\/."},{"issue":"1","key":"352_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-016-0669-1","volume":"14","author":"X-Y Ge","year":"2017","unstructured":"Ge X-Y, Yang W-H, Zhou J-H, Li B, Zhang W, Shi Z-L, et\u00a0al. Detection of alpha-and betacoronaviruses in rodents from Yunnan. China Virol J. 2017;14(1):1\u201311.","journal-title":"China Virol J"},{"key":"352_CR15","doi-asserted-by":"crossref","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et\u00a0al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv. 2020.01.22.914952.","DOI":"10.1101\/2020.01.22.914952"},{"key":"352_CR16","doi-asserted-by":"crossref","unstructured":"Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19): Springer; 2020. p. 23\u201331.","DOI":"10.1007\/978-981-15-4814-7_3"},{"key":"352_CR17","doi-asserted-by":"crossref","unstructured":"Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et\u00a0al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infections. 2020;9(1):221\u201336.","DOI":"10.1080\/22221751.2020.1719902"},{"key":"352_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.virusres.2015.02.025","volume":"206","author":"D Yang","year":"2015","unstructured":"Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3\u2032 and 5\u2032 ends. Virus Res. 2015;206:120\u201333.","journal-title":"Virus Res"},{"key":"352_CR19","doi-asserted-by":"crossref","unstructured":"Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Hu Y, et\u00a0al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv 2020.01.24.919183.","DOI":"10.1101\/2020.01.24.919183"},{"issue":"1","key":"352_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ygeno.2020.09.059","volume":"113","author":"A Rahimi","year":"2021","unstructured":"Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics. 2021;113(1):1221\u201332.","journal-title":"Genomics"},{"issue":"2","key":"352_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et\u00a0al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u201380.","journal-title":"Cell"},{"issue":"1","key":"352_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s11658-022-00311-1","volume":"27","author":"H Zalpoor","year":"2022","unstructured":"Zalpoor H, Akbari A, Samei A, Forghaniesfidvajani R, Kamali M, Afzalnia A, et\u00a0al. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies. Cell Mol Biol Lett. 2022;27(1):10.","journal-title":"Cell Mol Biol Lett"},{"issue":"6483","key":"352_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et\u00a0al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260\u20133.","journal-title":"Science"},{"key":"352_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104742","volume":"176","author":"B Coutard","year":"2020","unstructured":"Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176: 104742.","journal-title":"Antiviral Res"},{"key":"352_CR25","unstructured":"Liu W, Li H. COVID-19: attacks immune cells and interferences with antigen presentation through MHC-like decoy system."},{"issue":"11","key":"352_CR26","doi-asserted-by":"publisher","first-page":"e4208","DOI":"10.1093\/cid\/ciaa270","volume":"73","author":"P Mo","year":"2020","unstructured":"Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et\u00a0al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan. China Clin Infect Dis. 2020;73(11):e4208\u201313.","journal-title":"China Clin Infect Dis"},{"key":"352_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7754\/Clin.Lab.2020.200705","volume":"66","author":"M Saberiyan","year":"2020","unstructured":"Saberiyan M, Safi A, Kamel A, Movahhed-Abbasabad P, Miralimalek M, Afkhami H, et\u00a0al. An overview on the common laboratory parameter alterations and their related molecular pathways in screening for COVID-19 patients. Clin Lab. 2020;66:10.","journal-title":"Clin Lab"},{"issue":"1","key":"352_CR28","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.jinf.2020.04.004","volume":"81","author":"H Meng","year":"2020","unstructured":"Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et\u00a0al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan. China J Infect. 2020;81(1):e33\u20139.","journal-title":"China J Infect"},{"issue":"11","key":"352_CR29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1164\/rccm.202003-0543OC","volume":"201","author":"Y Du","year":"2020","unstructured":"Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et\u00a0al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"352_CR30","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.25882","volume":"92","author":"M Ye","year":"2020","unstructured":"Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et\u00a0al. Treatment with convalescent plasma for COVID-19 patients in Wuhan. China J Med Virol. 2020;92(10):1890\u2013901.","journal-title":"China J Med Virol"},{"issue":"10224","key":"352_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et\u00a0al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374.","journal-title":"Lancet"},{"key":"352_CR32","first-page":"754","volume":"7","author":"DJ Grint","year":"2021","unstructured":"Grint DJ, Wing K, Houlihan C, Gibbs HP, Evans SJ, Williamson E, et\u00a0al. Severity of SARS-CoV-2 alpha variant (B. 1.1. 7) in England. Clin Infect Dis. 2021;7:754.","journal-title":"Clin Infect Dis"},{"issue":"7858","key":"352_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1.7. Nature. 2021;593(7858):270\u20134.","journal-title":"Nature"},{"issue":"1","key":"352_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43168-021-00090-x","volume":"15","author":"P Deb","year":"2021","unstructured":"Deb P, Molla M, Ahmed M, Saif-Ur-Rahman K, Das MC, Das D. A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. Egypt J Bronchol. 2021;15(1):1\u201314.","journal-title":"Egypt J Bronchol"},{"issue":"12","key":"352_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et\u00a0al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757\u201373.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"352_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/v13030392","volume":"13","author":"F Grabowski","year":"2021","unstructured":"Grabowski F, Preibisch G, Gizi\u0144ski S, Kocha\u0144czyk M, Lipniacki T. SARS-CoV-2 variant of concern 202012\/01 has about twofold replicative advantage and acquires concerning mutations. Viruses. 2021;13(3):392.","journal-title":"Viruses"},{"issue":"7854","key":"352_CR37","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et\u00a0al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438\u201343.","journal-title":"Nature"},{"issue":"3","key":"352_CR38","doi-asserted-by":"publisher","first-page":"e01096","DOI":"10.1128\/Spectrum.01096-21","volume":"9","author":"M Alkhatib","year":"2021","unstructured":"Alkhatib M, Svicher V, Salpini R, Ambrosio FA, Bellocchi MC, Carioti L, et\u00a0al. SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021. Microbiol Spectrum. 2021;9(3):e01096-e1121.","journal-title":"Microbiol Spectrum"},{"issue":"9","key":"352_CR39","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et\u00a0al. Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348\u201361.","journal-title":"Cell"},{"issue":"23","key":"352_CR40","doi-asserted-by":"publisher","first-page":"2100447","DOI":"10.2807\/1560-7917.ES.2021.26.23.2100447","volume":"26","author":"B Roquebert","year":"2021","unstructured":"Roquebert B, Trombert-Paolantoni S, Haim-Boukobza S, Lecorche E, Verdurme L, Foulongne V, et\u00a0al. The SARS-CoV-2 B. 1.351 lineage (VOC \u03b2) is outgrowing the B. 1.1 7 lineage (VOC \u03b1) in some French regions in April 2021. Eurosurveillance. 2021;26(23):2100447.","journal-title":"Eurosurveillance"},{"key":"352_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112176","volume":"143","author":"A Khan","year":"2021","unstructured":"Khan A, Khan T, Ali S, Aftab S, Wang Y, Qiankun W, et\u00a0al. SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 2021;143: 112176.","journal-title":"Biomed Pharmacother"},{"key":"352_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-030-87324-0","volume-title":"Spike Protein Mutations Detected in Currently Circulating Strains SARS-CoV-2 Spike Protein Convergent Evolution","author":"D Focosi","year":"2021","unstructured":"Focosi D. Spike Protein Mutations Detected in Currently Circulating Strains SARS-CoV-2 Spike Protein Convergent Evolution. Berlin: Springer; 2021. p. 27\u201354."},{"issue":"4","key":"352_CR43","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/mco2.95","volume":"2","author":"X He","year":"2021","unstructured":"He X, He C, Hong W, Zhang K, Wei X. The challenges of COVID-19 Delta variant: prevention and vaccine development. MedComm. 2021;2(4):846\u201354.","journal-title":"MedComm"},{"issue":"3","key":"352_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5339\/qmj.2021.49","volume":"2021","author":"MA Hendaus","year":"2021","unstructured":"Hendaus MA, Jomha FA. Delta variant of COVID-19: a simple explanation. Qatar Med J. 2021;2021(3):49.","journal-title":"Qatar Med J"},{"key":"352_CR45","doi-asserted-by":"crossref","unstructured":"Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. medRxiv: the preprint server for health sciences. 2021.","DOI":"10.1101\/2021.06.21.21259268"},{"issue":"4","key":"352_CR46","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/clinpract11040093","volume":"11","author":"S Shiehzadegan","year":"2021","unstructured":"Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the delta variant B 1617 2 COVID-19. Clin Pract. 2021;11(4):778\u201384.","journal-title":"Clin Pract"},{"key":"352_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bjid.2021.101606","volume":"25","author":"M Mohammadi","year":"2021","unstructured":"Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis. 2021;25:8.","journal-title":"Braz J Infect Dis"},{"issue":"9","key":"352_CR48","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"352_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100255","volume":"2","author":"TN Starr","year":"2021","unstructured":"Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4): 100255.","journal-title":"Cell Rep Med"},{"issue":"7","key":"352_CR50","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/microorganisms9071542","volume":"9","author":"S Cherian","year":"2021","unstructured":"Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et\u00a0al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021;9(7):1542.","journal-title":"Microorganisms"},{"issue":"7","key":"352_CR51","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","volume":"2","author":"S Jangra","year":"2021","unstructured":"Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et\u00a0al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283\u20134.","journal-title":"Lancet Microbe"},{"issue":"27","key":"352_CR52","doi-asserted-by":"publisher","first-page":"E1059","DOI":"10.1503\/cmaj.1095949","volume":"193","author":"D Duong","year":"2021","unstructured":"Duong D. Alpha, Beta, Delta, Gamma: what\u2019s important to know about SARS-CoV-2 variants of concern? Can Med Assoc. 2021;193(27):E1059.","journal-title":"Can Med Assoc"},{"issue":"7","key":"352_CR53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jtm\/taab066","volume":"28","author":"CA Dos Santos","year":"2021","unstructured":"Dos Santos CA, Bezerra GVB, de Azevedo Marinho ARRA, Alves JC, Tanajura DM, Martins-Filho PR. SARS-CoV-2 genomic surveillance in Northeast Brazil: timing of emergence of the Brazilian variant of concern P1. J Travel Med. 2021;28(7):66.","journal-title":"J Travel Med"},{"issue":"1","key":"352_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s43856-021-00048-6","volume":"1","author":"RM Coutinho","year":"2021","unstructured":"Coutinho RM, Marquitti FMD, Ferreira LS, Borges ME, da Silva RLP, Canton O, et\u00a0al. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P1 variant. Commun Med. 2021;1(1):48.","journal-title":"Commun Med"},{"key":"352_CR55","unstructured":"Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DS, Mishra S, et\u00a0al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv. 2021:2021.02.26.21252554."},{"issue":"12","key":"352_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261492","volume":"16","author":"BMM Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves BMM, Franco RPV, Rodrigues AS. Maternal mortality associated with COVID-19 in Brazil in 2020 and 2021: comparison with non-pregnant women and men. PLoS ONE. 2021;16(12): e0261492.","journal-title":"PLoS ONE"},{"key":"352_CR57","doi-asserted-by":"crossref","unstructured":"de Andrade CLT, Lima SML, Martins M, Pereira CCdA, Portela MC. Has the age distribution of hospitalized Covid-19 patients changed in Brazil? : medRxiv; 2021.03.30.21254650.","DOI":"10.1101\/2021.03.30.21254650"},{"issue":"3","key":"352_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/vaccines9030243","volume":"9","author":"CE G\u00f3mez","year":"2021","unstructured":"G\u00f3mez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2\/COVID-19. Vaccines. 2021;9(3):243.","journal-title":"Vaccines"},{"issue":"5","key":"352_CR59","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et\u00a0al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295-310.e20.","journal-title":"Cell"},{"key":"352_CR60","doi-asserted-by":"crossref","unstructured":"Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, group Ps, Krammer F, et\u00a0al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021:2021.01.26.21250543.","DOI":"10.1101\/2021.01.26.21250543"},{"issue":"7852","key":"352_CR61","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","volume":"592","author":"JA Plante","year":"2021","unstructured":"Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et\u00a0al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116\u201321.","journal-title":"Nature"},{"key":"352_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102252","volume":"46","author":"C Tong","year":"2022","unstructured":"Tong C, Shi W, Zhang A, Shi Z. Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa. Travel Med Infect Dis. 2022;46: 102252.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"352_CR63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/22221751.2021.2023330","volume":"11","author":"FF Fang","year":"2022","unstructured":"Fang FF, Shi P-Y. Omicron: a drug developer\u2019s perspective. Emerg Microbes Infect. 2022;11(1):208\u201311.","journal-title":"Emerg Microbes Infect"},{"key":"352_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106716","volume":"191","author":"M Mohiuddin","year":"2022","unstructured":"Mohiuddin M, Kasahara K. Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options. Respir Med. 2022;191: 106716.","journal-title":"Respir Med"},{"key":"352_CR65","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","volume":"114","author":"E Petersen","year":"2022","unstructured":"Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et\u00a0al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B11529) - highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268\u201372.","journal-title":"Int J Infect Dis"},{"key":"352_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3104","author":"O Dyer","year":"2021","unstructured":"Dyer O. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n3104.","journal-title":"BMJ"},{"key":"352_CR67","doi-asserted-by":"crossref","DOI":"10.4414\/SMW.2021.w30120","volume":"151","author":"C Metzger","year":"2021","unstructured":"Metzger C, Lienhard R, Seth-Smith HMB, Roloff T, Wegner F, Sieber J, et\u00a0al. PCR performance in the SARS-CoV-2 Omicron variant of concern? Swiss Med Wkly. 2021;151: w30120.","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"352_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et\u00a0al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457-66.e4.","journal-title":"Cell"},{"key":"352_CR69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbrc.2021.12.079","volume":"590","author":"CS Lupala","year":"2022","unstructured":"Lupala CS, Ye Y, Chen H, Su X-D, Liu H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem Biophys Res Commun. 2022;590:34\u201341.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"352_CR70","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","volume":"62","author":"J Chen","year":"2022","unstructured":"Chen J, Wang R, Gilby NB, Wei G-W. Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412\u201322.","journal-title":"J Chem Inf Model"},{"key":"352_CR71","doi-asserted-by":"crossref","unstructured":"Guo K, Barrett BS, Mickens KL, Hasenkrug KJ, Santiago ML. Interferon resistance of emerging SARS-CoV-2 variants. BioRxiv. The preprint server for biology, 2021.03.20.436257.","DOI":"10.1101\/2021.03.20.436257"},{"issue":"12","key":"352_CR72","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1002\/jmv.27261","volume":"93","author":"C Padilla-Rojas","year":"2021","unstructured":"Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena L, et\u00a0al. Genomic analysis reveals a rapid spread and predominance of lambda (C 37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. J Med Virol. 2021;93(12):6845\u20139.","journal-title":"J Med Virol"},{"key":"352_CR73","doi-asserted-by":"crossref","unstructured":"Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, et\u00a0al. The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines. BioRxiv. 2021.08.25.457692.","DOI":"10.1101\/2021.08.25.457692"},{"issue":"46","key":"352_CR74","doi-asserted-by":"publisher","first-page":"977","DOI":"10.46234\/ccdcw2021.216","volume":"3","author":"W Bai","year":"2021","unstructured":"Bai W, Gu Y, Liu H, Zhou L. Epidemiology features and effectiveness of vaccination and non-pharmaceutical interventions of Delta and Lambda SARS-CoV-2 variants. China CDC Weekly. 2021;3(46):977.","journal-title":"China CDC Weekly"},{"key":"352_CR75","doi-asserted-by":"crossref","unstructured":"Henry BM, de Oliveira MHS, de Oliveira TB, Notarte KI, Lippi G. Symptomatology associated with the diffusion of the SARS-CoV-2 Lambda variant in Peru: an infodemiologic analysis. medRxiv. 2021.08.24.21262245.","DOI":"10.1101\/2021.08.24.21262245"},{"issue":"10","key":"352_CR76","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/microorganisms9102167","volume":"9","author":"M Moghaddar","year":"2021","unstructured":"Moghaddar M, Radman R, Macreadie I. Severity, pathogenicity and transmissibility of Delta and Lambda variants of SARS-CoV-2, toxicity of spike protein and possibilities for future prevention of COVID-19. Microorganisms. 2021;9(10):2167.","journal-title":"Microorganisms"},{"key":"352_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2021.06.001","volume":"63","author":"B Cosar","year":"2022","unstructured":"Cosar B, Karagulleoglu ZY, Unal S, Ince AT, Uncuoglu DB, Tuncer G, et\u00a0al. SARS-CoV-2 mutations and their viral variants. Cytokine Growth Factor Rev. 2022;63:10\u201322.","journal-title":"Cytokine Growth Factor Rev"},{"key":"352_CR78","doi-asserted-by":"crossref","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et\u00a0al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv. 2020.12.21.20248640.","DOI":"10.1101\/2020.12.21.20248640"},{"key":"352_CR79","doi-asserted-by":"crossref","unstructured":"Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, et\u00a0al. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. BioRxiv. 2021.07.28.454085.","DOI":"10.1101\/2021.07.28.454085"},{"issue":"6","key":"352_CR80","doi-asserted-by":"publisher","first-page":"20210008","DOI":"10.1098\/rsfs.2021.0008","volume":"11","author":"RM Anderson","year":"2021","unstructured":"Anderson RM, Vegvari C, Hollingsworth TD, Pi L, Maddren R, Ng CW, et\u00a0al. The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus. 2021;11(6):20210008.","journal-title":"Interface Focus"},{"issue":"3","key":"352_CR81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.vacune.2021.10.003","volume":"22","author":"M P\u00e9rez-Abeledo","year":"2021","unstructured":"P\u00e9rez-Abeledo M, Moreno JS. SARS-CoV-2 variants, a still unfinished story. Vacunas (English Edition). 2021;22(3):167\u201373.","journal-title":"Vacunas (English Edition)"},{"key":"352_CR82","first-page":"5","volume":"8","author":"F Rahimi","year":"2022","unstructured":"Rahimi F, Kamali N, Bezmin AT. The Mu strain: the last but not least circulating \u2018variant of interest\u2019 potentially affecting the COVID-19 pandemic. Fut Med. 2022;8:5\u20138.","journal-title":"Fut Med"},{"key":"352_CR83","doi-asserted-by":"crossref","unstructured":"Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A, et\u00a0al. Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. BioRxiv. 2021.09.06.459005.","DOI":"10.1101\/2021.09.06.459005"},{"key":"352_CR84","doi-asserted-by":"publisher","first-page":"105038","DOI":"10.1016\/j.meegid.2021.105038","volume":"95","author":"K Laiton-Donato","year":"2021","unstructured":"Laiton-Donato K, Franco-Mu\u00f1oz C, \u00c1lvarez-D\u00edaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Prada DA, et\u00a0al. Characterization of the emerging B 1621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021;95:105038.","journal-title":"Infect Genet Evol"},{"issue":"5","key":"352_CR85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.medj.2022.03.009","volume":"3","author":"T Darling","year":"2022","unstructured":"Darling T, Ying B, Whitener B, VanBlargan LA, Bricker T, Liang C-Y, et\u00a0al. mRNA-1273 and Ad26 COV2 S vaccines protect against the B 1621 variant of SARS-CoV-2. Med. 2022;3(5):309\u201324.","journal-title":"Med"},{"issue":"6","key":"352_CR86","doi-asserted-by":"publisher","first-page":"789","DOI":"10.24272\/j.issn.2095-8137.2021.343","volume":"42","author":"X Xie","year":"2021","unstructured":"Xie X, Han J-B, Ma G, Feng X-L, Li X, Zou Q-C, et\u00a0al. Emerging SARS-CoV-2 B 1621\/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res. 2021;42(6):789.","journal-title":"Zool Res"},{"key":"352_CR87","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","volume":"9","author":"Y Weisblum","year":"2020","unstructured":"Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et\u00a0al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9: e61312.","journal-title":"eLife"},{"issue":"3","key":"352_CR88","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"Z Liu","year":"2021","unstructured":"Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et\u00a0al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477\u20138.","journal-title":"Cell Host Microbe"},{"issue":"7857","key":"352_CR89","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et\u00a0al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130\u20135.","journal-title":"Nature"},{"key":"352_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112276","volume":"144","author":"RJ Malek","year":"2021","unstructured":"Malek RJ, Bill CA, Vines CM. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. Biomed Pharmacother. 2021;144: 112276.","journal-title":"Biomed Pharmacother"},{"issue":"15","key":"352_CR91","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et\u00a0al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"352_CR92","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et\u00a0al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238\u201351.","journal-title":"N Engl J Med"},{"issue":"6531","key":"352_CR93","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et\u00a0al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850\u20134.","journal-title":"Science"},{"issue":"2","key":"352_CR94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202\u201321.","journal-title":"Clin Microbiol Infect"},{"key":"352_CR95","unstructured":"COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide World Health Organization; 2022. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"352_CR96","first-page":"1","volume":"3","author":"V Mouro","year":"2022","unstructured":"Mouro V, Fischer A. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. Mucosal Immunol. 2022;3:1\u20131.","journal-title":"Mucosal Immunol"},{"issue":"7","key":"352_CR97","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells11071182","volume":"11","author":"M Aileni","year":"2022","unstructured":"Aileni M, Rohela GK, Jogam P, Soujanya S, Zhang B. Biotechnological perspectives to combat the COVID-19 pandemic: precise diagnostics and inevitable vaccine paradigms. Cells. 2022;11(7):1182.","journal-title":"Cells"},{"issue":"1","key":"352_CR98","first-page":"15","volume":"12","author":"FZ Simnani","year":"2022","unstructured":"Simnani FZ, Singh D, Kaur R. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. Biotech. 2022;12(1):15.","journal-title":"Biotech"},{"issue":"9","key":"352_CR99","doi-asserted-by":"publisher","first-page":"e23937","DOI":"10.1002\/jcla.23937","volume":"35","author":"X Han","year":"2021","unstructured":"Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: ttypes, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"352_CR100","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/vaccines10040521","volume":"10","author":"K Lukaszuk","year":"2022","unstructured":"Lukaszuk K, Podolak A, Malinowska P, Lukaszuk J, Jakiel G. Cross-reactivity between half doses of Pfizer and AstraZeneca vaccines\u2014a preliminary study. Vaccines (Basel). 2022;10(4):521.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"352_CR101","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","volume":"10","author":"Q Liu","year":"2021","unstructured":"Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132.","journal-title":"Infect Dis Poverty"},{"key":"352_CR102","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252\u201360.","journal-title":"Int J Infect Dis"},{"key":"352_CR103","doi-asserted-by":"crossref","unstructured":"Shapiro J, Dean NE, Madewell ZJ, Yang Y, Halloran ME, Longini I. Efficacy estimates for various COVID-19 vaccines: what we know from the literature and reports. medRxiv. 2021.05.20.21257461.","DOI":"10.1101\/2021.05.20.21257461"},{"key":"352_CR104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/vaccines9111305","volume":"9","author":"K Hayawi","year":"2021","unstructured":"Hayawi K, Shahriar S, Serhani MA. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines. 2021;9:11.","journal-title":"Vaccines"},{"issue":"2","key":"352_CR105","first-page":"187","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B117 and B1351. Variants. 2021;385(2):187\u20139.","journal-title":"Variants."},{"issue":"10286","key":"352_CR106","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et\u00a0al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet (London, England). 2021;397(10286):1725\u201335.","journal-title":"Lancet (London, England)"},{"issue":"15","key":"352_CR107","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et\u00a0al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323.","journal-title":"N Engl J Med"},{"key":"352_CR108","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1136\/bmj.n1943","volume":"374","author":"H Chung","year":"2021","unstructured":"Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et\u00a0al. Effectiveness of BNT162b2 and mRNA-1273 Covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe Covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:1943.","journal-title":"BMJ"},{"issue":"7","key":"352_CR109","doi-asserted-by":"publisher","first-page":"e0254920","DOI":"10.1371\/journal.pone.0254920","volume":"16","author":"A Yassi","year":"2021","unstructured":"Yassi A, Grant JM, Lockhart K, Barker S, Sprague S, Okpani AI, et\u00a0al. Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: a 14-month observational study using surveillance data. PLoS ONE. 2021;16(7):e0254920.","journal-title":"PLoS ONE"},{"issue":"7","key":"352_CR110","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et\u00a0al. Effectiveness of Covid-19 vaccines against the B16172 (Delta) variant. N Engl J Med. 2021;385(7):585\u201394.","journal-title":"N Engl J Med"},{"key":"352_CR111","doi-asserted-by":"crossref","unstructured":"Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et\u00a0al. Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. medRxiv. 2021:2021.06.28.21259420.","DOI":"10.1101\/2021.06.28.21259420"},{"key":"352_CR112","doi-asserted-by":"crossref","unstructured":"Tang P, Hasan MR. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. 2021;27(12):2136\u201343.","DOI":"10.1038\/s41591-021-01583-4"},{"key":"352_CR113","doi-asserted-by":"crossref","unstructured":"Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, M\u00f8lbak K, et\u00a0al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study. medRxiv. 2021.12.20.21267966.","DOI":"10.1101\/2021.12.20.21267966"},{"issue":"10287","key":"352_CR114","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et\u00a0al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet (London, England). 2021;397(10287):1819\u201329.","journal-title":"Lancet (London, England)"},{"key":"352_CR115","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.lanepe.2021.100171","volume":"8","author":"T Charmet","year":"2021","unstructured":"Charmet T, Schaeffer L, Grant R, Galmiche S, Ch\u00e9ny O, Von Platen C, et\u00a0al. Impact of original, B117, and B1351\/P1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: results from a nationwide case-control study in France. Lancet Reg Health Eur. 2021;8:100171.","journal-title":"Lancet Reg Health Eur."},{"issue":"10309","key":"352_CR116","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et\u00a0al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407\u201316.","journal-title":"Lancet"},{"key":"352_CR117","doi-asserted-by":"crossref","unstructured":"Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance\u2014eight U.S. locations, December 2020\u2013August 2021. MMWR morbidity and mortality weekly report. 2021;70(34):1167\u20139.","DOI":"10.15585\/mmwr.mm7034e4"},{"key":"352_CR118","doi-asserted-by":"crossref","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et\u00a0al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. 2021:2021.12.14.21267615.","DOI":"10.1101\/2021.12.14.21267615"},{"key":"352_CR119","doi-asserted-by":"crossref","unstructured":"Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et\u00a0al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614\u201321.","DOI":"10.1038\/s41591-021-01446-y"},{"issue":"35","key":"352_CR120","doi-asserted-by":"publisher","first-page":"2100793","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","volume":"26","author":"E Sepp\u00e4l\u00e4","year":"2021","unstructured":"Sepp\u00e4l\u00e4 E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, et\u00a0al. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26(35):2100793.","journal-title":"Euro Surveill"},{"key":"352_CR121","doi-asserted-by":"crossref","unstructured":"Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Galanis E, et\u00a0al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. Clin Infect Dis. 2021.","DOI":"10.1101\/2021.09.20.21263875"},{"key":"352_CR122","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068848","volume":"375","author":"KJ Bruxvoort","year":"2021","unstructured":"Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et\u00a0al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants of SARS-CoV-2: test negative case\u2013control study. BMJ. 2021;375: e068848.","journal-title":"BMJ"},{"key":"352_CR123","doi-asserted-by":"crossref","unstructured":"Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et\u00a0al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. medRxiv. 2022:2022.01.07.22268919.","DOI":"10.1101\/2022.01.07.22268919"},{"key":"352_CR124","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et\u00a0al. Effectiveness of the Pfizer\u2013BioNTech and Oxford\u2013AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case\u2013control study. BMJ. 2021;373:1088.","journal-title":"BMJ"},{"issue":"29","key":"352_CR125","doi-asserted-by":"publisher","first-page":"2100670","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100670","volume":"26","author":"E Kissling","year":"2021","unstructured":"Kissling E, Hooiveld M, Sandonis Mart\u00edn V, Mart\u00ednez-Baz I, William N, Vilcu A-M, et\u00a0al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):2100670.","journal-title":"Euro Surveill"},{"issue":"11","key":"352_CR126","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S1473-3099(21)00289-9","volume":"21","author":"M Shrotri","year":"2021","unstructured":"Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et\u00a0al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021;21(11):1529\u201338.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"352_CR127","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/vaccines9060628","volume":"9","author":"ME Flacco","year":"2021","unstructured":"Flacco ME, Soldato G, Acuti Martellucci C, Carota R, Di Luzio R, Caponetti A, et\u00a0al. Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel). 2021;9(6):628.","journal-title":"Vaccines (Basel)"},{"issue":"20","key":"352_CR128","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et\u00a0al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B1351 variant. N Engl J Med. 2021;384(20):1885\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"352_CR129","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1038\/s41467-021-26459-6","volume":"12","author":"MDT Hitchings","year":"2021","unstructured":"Hitchings MDT, Ranzani OT, Dorion M, D\u2019Agostini TL, de Paula RC, de Paula OFP, et\u00a0al. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in S\u00e3o Paulo. Nat Commun. 2021;12(1):6220.","journal-title":"Nat Commun"},{"key":"352_CR130","unstructured":"Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S, et\u00a0al. Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B\u00b7 1\u00b7 617\u00b7 2 delta variant despite reduced virus neutralisation. Preprint with the Lancet."},{"issue":"10282","key":"352_CR131","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et\u00a0al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England). 2021;397(10282):1351\u201362.","journal-title":"Lancet (London, England)."},{"issue":"10319","key":"352_CR132","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(21)02754-9","volume":"399","author":"SV Katikireddi","year":"2022","unstructured":"Katikireddi SV, Cerqueira-Silva T, Vasileiou E, Robertson C, Amele S, Pan J, et\u00a0al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet. 2022;399(10319):25\u201335.","journal-title":"Lancet"},{"key":"352_CR133","first-page":"100025","volume":"1","author":"MDT Hitchings","year":"2021","unstructured":"Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et\u00a0al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case\u2013control study. Lancet Reg Health Am. 2021;1:100025.","journal-title":"Lancet Reg Health Am."},{"key":"352_CR134","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1136\/bmj.n2015","volume":"374","author":"OT Ranzani","year":"2021","unstructured":"Ranzani OT, Hitchings MDT, Dorion M, D\u2019Agostini TL, de Paula RC, de Paula OFP, et\u00a0al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of Covid-19 in Brazil: test negative case\u2013control study. BMJ. 2021;374:2015.","journal-title":"BMJ"},{"issue":"1","key":"352_CR135","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","volume":"10","author":"XN Li","year":"2021","unstructured":"Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et\u00a0al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case\u2013control real-world study. Emerg Microbes Infect. 2021;10(1):1751\u20139.","journal-title":"Emerg Microbes Infect"},{"issue":"20","key":"352_CR136","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et\u00a0al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899\u2013909.","journal-title":"N Engl J Med"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-022-00352-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-022-00352-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-022-00352-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T13:27:26Z","timestamp":1675862846000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-022-00352-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1186\/s11658-022-00352-6","relation":{},"ISSN":["1425-8153","1689-1392"],"issn-type":[{"value":"1425-8153","type":"print"},{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known conflict of interests\/competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}